What Is Lytenava and Why Does It Matter for Retina Billing?
Lytenava (bevacizumab-vikg) is the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, approved on July 24, 2026. As of October 2026, the drug has a CMS pass-through C-code for reimbursement, with commercial launch expected before the end of 2026 and a permanent J-code anticipated by April 2027. Research published in Ophthalmology projects that if an FDA-approved ophthalmic bevacizumab replaces off-label repackaged Avastin, Medicare Part B retina drug costs could increase by 15 to 30 percent depending on the final price point, because the $70 per injection compounded Avastin pathway may be curtailed under the Drug Quality and Security Act.
The cost paradox: Off-label repackaged bevacizumab costs Medicare about $70 per dose. If Lytenava launches at $500 per dose, Medicare retina drug spending increases by an estimated $457 million annually. At $900, the increase reaches $897 million, roughly a 30% jump.
The DQSA risk: Once an FDA-approved ophthalmic bevacizumab exists, the Drug Quality and Security Act may prohibit compounding pharmacies from repackaging Avastin for intravitreal use, eliminating the low-cost option entirely.
What practices must do now: Ophthalmology practices need to understand the new billing codes, track the pricing as it is announced, and prepare their drug acquisition and buy-and-bill workflows for a product that could cost 5 to 12 times more than what they pay today for compounded bevacizumab.
What FDA Approved on July 24, 2026
On July 24, 2026, the FDA approved Lytenava (bevacizumab-vikg), developed by Outlook Therapeutics, as the first ophthalmic formulation of bevacizumab specifically manufactured and labeled for intravitreal injection. The approval covers the treatment of neovascular (wet) age-related macular degeneration (nAMD).
This is not a biosimilar in the traditional sense. Outlook Therapeutics filed a Biologics License Application (BLA), and the FDA granted Lytenava 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act (BPCIA). That exclusivity period means no biosimilar to Lytenava itself can enter the market until at least 2038, which has significant pricing implications.
The approval followed a lengthy regulatory process that included a Complete Response Letter in December 2025, a resubmitted BLA accepted in June 2026, and a PDUFA target date of July 29, 2026. Outlook Therapeutics confirmed that commercial launch is planned before the end of calendar year 2026, with CMS assigning a pass-through C-code effective October 1, 2026, to support initial reimbursement. A permanent HCPCS J-code is expected by April 2027.
Why Would an FDA-Approved Bevacizumab Raise Costs?
This is the counterintuitive billing reality that every retina practice needs to understand. In every other therapeutic area, biosimilars and new FDA-approved formulations drive costs down. In intravitreal bevacizumab, the opposite may happen.
For over 20 years, ophthalmologists have used off-label bevacizumab (Avastin, manufactured by Genentech as an oncology drug) for retinal diseases by having compounding pharmacies repackage the IV formulation into intravitreal-ready syringes. This off-label pathway costs Medicare approximately $70 per injection and patients roughly $18 in cost-sharing, making it by far the cheapest anti-VEGF option available.
| Anti-VEGF Drug | July 2026 Medicare Part B Payment Limit | Patient Cost-Sharing (20%) |
|---|---|---|
| Bevacizumab (repackaged, off-label) | ~$75 per 10 mg | ~$18 |
| Ranibizumab (Lucentis) 0.5 mg | ~$255 | ~$64 |
| Aflibercept (Eylea) 2 mg | ~$1,487 | ~$361 |
| Aflibercept (Eylea HD) 8 mg | ~$2,389 | ~$597 |
| Faricimab (Vabysmo) 6 mg | ~$1,943 | ~$486 |
| Lytenava (bevacizumab-vikg) | TBD (launch pending) | TBD |
The research behind the cost projections was published in Ophthalmology (the AAO journal) by Ravi Parikh, M.D., and colleagues at NYU Langone Health. Using Medicare ASP data and market share analysis, the study modeled two price scenarios. At $500 per dose, Medicare Part B anti-VEGF spending would increase by $457 million annually (15.2%). At $900 per dose, the increase reaches $897 million (29.8%). In neither scenario does switching ranibizumab and aflibercept patients to their respective biosimilars offset the cost increase from losing the $70 compounded bevacizumab pathway.
How Does the DQSA Affect Compounded Bevacizumab?
The Drug Quality and Security Act (DQSA) restricts compounding pharmacies from producing copies of commercially available drugs. Once Lytenava is commercially available as an FDA-approved ophthalmic bevacizumab, the legal basis for compounding pharmacies to continue repackaging Avastin for intravitreal use becomes uncertain.
This is the mechanism that could eliminate the $70 per injection price point. If the FDA or state pharmacy boards enforce the DQSA against compounding pharmacies that repackage Avastin after Lytenava launches, every retina practice that currently uses compounded bevacizumab as its first-line anti-VEGF will need to switch to either Lytenava at whatever its launch price is, or to another on-label anti-VEGF at a significantly higher cost.
In our experience matching ophthalmology providers with billing partners, the practices most exposed to this shift are high-volume retina groups that built their buy-and-bill economics around the compounded bevacizumab price. A practice injecting 200 eyes per month with compounded bevacizumab at $70 per dose has a drug acquisition cost of roughly $14,000 per month. If that shifts to $500 per dose, the monthly drug cost jumps to $100,000. The margin on buy-and-bill, which currently favors the practice on the spread between acquisition cost and Medicare allowable, reverses if the ASP-based reimbursement does not keep pace with the new drug price. For practices already tracking their retinal imaging and diagnostic billing, the drug cost shift adds a second revenue variable that must be modeled before Lytenava launches.
The Lytenava approval is about to reshape the economics of retina billing. If your practice relies on compounded bevacizumab and has not modeled what a $500 or $900 per dose replacement means for your buy-and-bill margin, a billing partner with ophthalmology-specific drug reimbursement expertise can run that analysis before the price is set. Ophthalmology Bill Co matches your practice with vetted billing companies, free.
How to Prepare Your Practice for the Lytenava Launch
These six steps protect your retina billing workflow before the drug hits the market.
1. Audit your current compounded bevacizumab volume. Pull the number of intravitreal bevacizumab injections billed per month, the acquisition cost per dose from your compounding pharmacy, and the Medicare or commercial reimbursement per injection. This is your baseline for modeling the cost shift.
2. Model the buy-and-bill impact at multiple price points. Run the math at $500, $700, and $900 per dose. Calculate what happens to your margin when the drug acquisition cost changes but the ASP-based reimbursement lags behind. Medicare Part B reimburses at ASP plus 6%, so the first two quarters of billing a new drug often carry a reimbursement gap.
3. Track the J-code and ASP timeline. Lytenava currently has a pass-through C-code effective October 1, 2026. A permanent J-code is expected by April 2027. Until the J-code is active, billing will use miscellaneous drug codes, which slow reimbursement and require manual pricing.
4. Contact your compounding pharmacy. Ask whether they plan to continue repackaging Avastin for intravitreal use after Lytenava launches commercially. Their answer determines whether you have a transition window or a hard cutover.
5. Review payer step therapy requirements. Some commercial payers and Medicare Advantage plans may implement step therapy requiring Lytenava or another FDA-approved agent before authorizing higher-cost anti-VEGFs. Others may continue to allow off-label bevacizumab if it remains available. Verify each payer’s position.
6. Update your drug inventory and ordering workflow. If your practice stores and administers anti-VEGF drugs in-office, the switch from compounded bevacizumab to Lytenava changes your cold chain, inventory management, and waste tracking. Plan the operational transition alongside the billing transition.
Lytenava Billing Codes and Reimbursement
As of October 2026, Lytenava has a CMS pass-through C-code for outpatient hospital and ASC billing. For physician office (place of service 11) billing, practices will use a miscellaneous J-code (such as J3490 or J3590) with the drug name, NDC, and dosage specified in the claim remarks until the permanent J-code is assigned, which Outlook Therapeutics expects by April 2027.
The intravitreal injection procedure code remains CPT 67028, the same code used for all intravitreal anti-VEGF injections regardless of which drug is administered. The procedure reimbursement does not change. What changes is the drug reimbursement line, which will shift from the compounded bevacizumab ASP to the Lytenava ASP once the J-code is active.
One question we hear constantly from ophthalmology practice managers is how long the reimbursement gap lasts on a newly launched drug. The answer is typically two to three quarters. Medicare Part B calculates ASP from manufacturer-reported sales data, and the first ASP for a new drug is based on the wholesale acquisition cost (WAC), which is often higher than the eventual ASP. Practices that bill Lytenava in the first quarter after launch should expect that the reimbursement may not cover the full acquisition cost until the ASP stabilizes. For a deeper look at how ophthalmology billing partners handle drug reimbursement transitions, see our ophthalmology billing experts directory.
Retina Anti-VEGF Strategy After Lytenava
Providers often come to us after a drug pricing shift has already compressed their margins. The practices that navigate the Lytenava transition successfully will be the ones that model the economics before the drug launches, not after.
If compounded bevacizumab remains available through your pharmacy, the immediate pressure is lower. Your practice can continue using the compounded product while monitoring whether DQSA enforcement or payer step therapy policies force a switch. If your compounding pharmacy signals that it will stop repackaging Avastin, the timeline accelerates.
Practices with a mixed anti-VEGF portfolio, using bevacizumab for first-line treatment and aflibercept or faricimab for non-responders, face the most complex transition. The drug that currently costs $70 could soon cost $500 or more, while the drugs that cost $1,400 to $2,400 remain unchanged. The cost curve between first-line and second-line therapy compresses, which changes the economic logic behind step therapy protocols and may shift which drug practices choose to stock.
For practices managing diagnosis coding alongside the drug billing transition, the ICD-10 coding for refractive and retinal conditions must remain accurate regardless of which anti-VEGF is administered. The diagnosis drives the medical necessity for the injection, and a coding error on the diagnosis line can deny the drug claim even when the procedure code and drug code are correct.
Frequently Asked Questions
Lytenava is the first FDA-approved ophthalmic formulation of bevacizumab, manufactured specifically for intravitreal injection to treat wet age-related macular degeneration. It was approved on July 24, 2026, by FDA and is developed by Outlook Therapeutics. Commercial launch is expected before the end of 2026.
The final US launch price has not been announced as of October 2026. Research published in Ophthalmology modeled scenarios at $500 and $900 per 1.25 mg dose. For comparison, off-label compounded bevacizumab currently costs Medicare approximately $70 to $75 per injection, making any FDA-approved ophthalmic formulation significantly more expensive.
It depends on DQSA enforcement. The Drug Quality and Security Act restricts compounding of commercially available drugs. Once Lytenava is commercially available, the legal basis for continued Avastin repackaging becomes uncertain. Some compounding pharmacies may continue while others may not. Contact your pharmacy directly for their plans.
As of October 2026, Lytenava has a CMS pass-through C-code for hospital outpatient and ASC settings. For physician office billing, use a miscellaneous J-code (J3490 or J3590) with drug name and NDC in the remarks until a permanent J-code is assigned, expected by April 2027. The injection procedure code remains CPT 67028.
Lytenava is approved only for wet AMD. It is an ophthalmic formulation of bevacizumab, so it occupies the same therapeutic space as off-label Avastin but with FDA-approved labeling. It does not replace ranibizumab (Lucentis), aflibercept (Eylea), or faricimab (Vabysmo), which have different molecular structures and approved indications.
Research from NYU Langone Health projects that if an ophthalmic bevacizumab priced at $500 per dose replaces the $70 compounded bevacizumab, annual Medicare Part B anti-VEGF spending increases by $457 million (15.2%). At $900 per dose, the increase reaches $897 million (29.8%). Biosimilar use of ranibizumab and aflibercept would offset less than 29% of this increase.
Next Steps
Audit your current compounded bevacizumab volume and buy-and-bill margin to establish your baseline before Lytenava pricing is announced.
Contact your compounding pharmacy to confirm whether they plan to continue Avastin repackaging after Lytenava launches commercially.
Review your retinal imaging billing at CPT 92134 to ensure your diagnostic coding supports the anti-VEGF injection claims.
Ready to model the billing impact before the drug launches? Get matched with an ophthalmology billing partner who handles drug reimbursement transitions.
The Lytenava approval could be the most expensive drug pricing shift in retina billing history. Whether compounded bevacizumab survives or disappears, your practice needs a billing partner who understands anti-VEGF drug economics, buy-and-bill margin modeling, and the J-code transition timeline. Ophthalmology Bill Co matches your practice with vetted billing companies that specialize in retina and anterior segment billing. Free quotes, all 50 states, rates starting at 2.95%.
